Financials data is unavailable for this security.
View more
Year on year Sinotherapeutics Inc had net income fall -34.29% from 92.94m to 61.07m despite a 21.13% increase in revenues from 247.56m to 299.87m. An increase in the cost of goods sold as a percentage of sales from 27.65% to 44.52% was a component in the falling net income despite rising revenues.
| Gross margin | 53.66% |
|---|---|
| Net profit margin | 24.40% |
| Operating margin | 27.58% |
| Return on assets | 7.88% |
|---|---|
| Return on equity | 9.02% |
| Return on investment | 8.54% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Sinotherapeutics Inc fell by 121.36m. However, the company earned 12.96m from its operations for a Cash Flow Margin of 4.32%. In addition the company used 107.57m on investing activities and also paid 28.27m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.73 |
|---|---|
| Tangible book value per share | 2.64 |
More ▼
Balance sheet in CNYView more
| Current ratio | 8.91 |
|---|---|
| Quick ratio | 7.95 |
| Total debt/total equity | 0.00002 |
|---|---|
| Total debt/total capital | 0.00002 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -33.87% and -34.29%, respectively.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 27.05% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 57.07 |
More ▼
